Fatigue  ||| S:0 E:8 ||| NNP
in  ||| S:8 E:11 ||| IN
Sjogren ||| S:11 E:18 ||| NNP
's  ||| S:18 E:21 ||| POS
syndrome ||| S:21 E:29 ||| NN
:  ||| S:29 E:31 ||| :
relationship  ||| S:31 E:44 ||| NN
with  ||| S:44 E:49 ||| IN
fibromyalgia ||| S:49 E:61 ||| NN
,  ||| S:61 E:63 ||| ,
clinical  ||| S:63 E:72 ||| JJ
and  ||| S:72 E:76 ||| CC
biologic  ||| S:76 E:85 ||| JJ
features  ||| S:85 E:94 ||| NNS
More  ||| S:94 E:99 ||| RBR
than  ||| S:99 E:104 ||| IN
two  ||| S:104 E:108 ||| CD
third  ||| S:108 E:114 ||| JJ
of  ||| S:114 E:117 ||| IN
patients  ||| S:117 E:126 ||| NNS
with  ||| S:126 E:131 ||| IN
primary  ||| S:131 E:139 ||| JJ
Sjögren ||| S:139 E:146 ||| NNP
's  ||| S:146 E:149 ||| POS
syndrome  ||| S:149 E:158 ||| NN
( ||| S:158 E:159 ||| -LRB-
SS ||| S:159 E:161 ||| NNP
)  ||| S:161 E:163 ||| -RRB-
report  ||| S:163 E:170 ||| NN
fatigue ||| S:170 E:177 ||| NN
.  ||| S:177 E:179 ||| .
Despite  ||| S:179 E:187 ||| IN
its  ||| S:187 E:191 ||| PRP$
clinical  ||| S:191 E:200 ||| JJ
relevance ||| S:200 E:209 ||| NN
,  ||| S:209 E:211 ||| ,
only  ||| S:211 E:216 ||| RB
a  ||| S:216 E:218 ||| DT
few  ||| S:218 E:222 ||| JJ
studies  ||| S:222 E:230 ||| NNS
have  ||| S:230 E:235 ||| VBP
examined  ||| S:235 E:244 ||| VBN
the  ||| S:244 E:248 ||| DT
relationship  ||| S:248 E:261 ||| NN
of  ||| S:261 E:264 ||| IN
fatigue  ||| S:264 E:272 ||| NN
with  ||| S:272 E:277 ||| IN
the  ||| S:277 E:281 ||| DT
presence  ||| S:281 E:290 ||| NN
of  ||| S:290 E:293 ||| IN
an  ||| S:293 E:296 ||| DT
overlapping  ||| S:296 E:308 ||| JJ
Fibromyalgia  ||| S:308 E:321 ||| NNP
( ||| S:321 E:322 ||| -LRB-
FM ||| S:322 E:324 ||| NNP
)  ||| S:324 E:326 ||| -RRB-
and  ||| S:326 E:330 ||| CC
other  ||| S:330 E:336 ||| JJ
clinical  ||| S:336 E:345 ||| JJ
and  ||| S:345 E:349 ||| CC
biological  ||| S:349 E:360 ||| JJ
variables ||| S:360 E:369 ||| NNS
.  ||| S:369 E:371 ||| .
The  ||| S:371 E:375 ||| DT
aim  ||| S:375 E:379 ||| NN
of  ||| S:379 E:382 ||| IN
this  ||| S:382 E:387 ||| DT
study  ||| S:387 E:393 ||| NN
was  ||| S:393 E:397 ||| VBD
to  ||| S:397 E:400 ||| TO
assess  ||| S:400 E:407 ||| VB
the  ||| S:407 E:411 ||| DT
relationship  ||| S:411 E:424 ||| NN
between  ||| S:424 E:432 ||| IN
fatigue  ||| S:432 E:440 ||| NN
and  ||| S:440 E:444 ||| CC
SS  ||| S:444 E:447 ||| NNP
disease  ||| S:447 E:455 ||| NN
activity  ||| S:455 E:464 ||| NN
and  ||| S:464 E:468 ||| CC
damage ||| S:468 E:474 ||| NN
,  ||| S:474 E:476 ||| ,
FM ||| S:476 E:478 ||| NNP
,  ||| S:478 E:480 ||| ,
widespread  ||| S:480 E:491 ||| JJ
pain ||| S:491 E:495 ||| NN
,  ||| S:495 E:497 ||| ,
and  ||| S:497 E:501 ||| CC
mood  ||| S:501 E:506 ||| NN
disorders ||| S:506 E:515 ||| NNS
;  ||| S:515 E:517 ||| :
finally ||| S:517 E:524 ||| RB
,  ||| S:524 E:526 ||| ,
the  ||| S:526 E:530 ||| DT
possible  ||| S:530 E:539 ||| JJ
correlation  ||| S:539 E:551 ||| NN
between  ||| S:551 E:559 ||| IN
fatigue  ||| S:559 E:567 ||| NN
and  ||| S:567 E:571 ||| CC
a  ||| S:571 E:573 ||| DT
panel  ||| S:573 E:579 ||| NN
of  ||| S:579 E:582 ||| IN
cytokines  ||| S:582 E:592 ||| JJ
likely  ||| S:592 E:599 ||| JJ
to  ||| S:599 E:602 ||| TO
drive  ||| S:602 E:608 ||| VB
the  ||| S:608 E:612 ||| DT
immunopathological  ||| S:612 E:631 ||| JJ
process  ||| S:631 E:639 ||| NN
of  ||| S:639 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
disease  ||| S:646 E:654 ||| NN
has  ||| S:654 E:658 ||| VBZ
been  ||| S:658 E:663 ||| VBN
examined ||| S:663 E:671 ||| VBN
.  ||| S:671 E:673 ||| .
Thirty-five  ||| S:673 E:685 ||| CD
female  ||| S:685 E:692 ||| JJ
patients  ||| S:692 E:701 ||| NNS
with  ||| S:701 E:706 ||| IN
primary  ||| S:706 E:714 ||| JJ
SS  ||| S:714 E:717 ||| NNP
were  ||| S:717 E:722 ||| VBD
consecutively  ||| S:722 E:736 ||| JJ
enrolled ||| S:736 E:744 ||| NN
;  ||| S:744 E:746 ||| :
for  ||| S:746 E:750 ||| IN
each  ||| S:750 E:755 ||| DT
patient  ||| S:755 E:763 ||| NN
the  ||| S:763 E:767 ||| DT
Sjögren ||| S:767 E:774 ||| NNP
's  ||| S:774 E:777 ||| POS
Syndrome  ||| S:777 E:786 ||| NNP
Disease  ||| S:786 E:794 ||| NNP
Damage  ||| S:794 E:801 ||| NNP
Index  ||| S:801 E:807 ||| NNP
( ||| S:807 E:808 ||| -LRB-
SSDDI ||| S:808 E:813 ||| NNP
)  ||| S:813 E:815 ||| -RRB-
and  ||| S:815 E:819 ||| CC
the  ||| S:819 E:823 ||| DT
Sjögren ||| S:823 E:830 ||| NNP
's  ||| S:830 E:833 ||| POS
Syndrome  ||| S:833 E:842 ||| NNP
Disease  ||| S:842 E:850 ||| NNP
Activity  ||| S:850 E:859 ||| NNP
Index  ||| S:859 E:865 ||| NNP
( ||| S:865 E:866 ||| -LRB-
SSDAI ||| S:866 E:871 ||| NNP
)  ||| S:871 E:873 ||| -RRB-
were  ||| S:873 E:878 ||| VBD
calculated ||| S:878 E:888 ||| VBN
.  ||| S:888 E:890 ||| .
Patients  ||| S:890 E:899 ||| NNS
rated  ||| S:899 E:905 ||| VBN
pain ||| S:905 E:909 ||| NN
,  ||| S:909 E:911 ||| ,
fatigue  ||| S:911 E:919 ||| NN
and  ||| S:919 E:923 ||| CC
disease  ||| S:923 E:931 ||| NN
activity  ||| S:931 E:940 ||| NN
using  ||| S:940 E:946 ||| VBG
a  ||| S:946 E:948 ||| DT
100-mm  ||| S:948 E:955 ||| NNP
VAS  ||| S:955 E:959 ||| NNP
and  ||| S:959 E:963 ||| CC
completed  ||| S:963 E:973 ||| VBD
Health  ||| S:973 E:980 ||| NNP
Assessment  ||| S:980 E:991 ||| NNP
Questionnaire  ||| S:991 E:1005 ||| NNP
( ||| S:1005 E:1006 ||| -LRB-
HAQ ||| S:1006 E:1009 ||| NNP
) ||| S:1009 E:1010 ||| -RRB-
,  ||| S:1010 E:1012 ||| ,
the  ||| S:1012 E:1016 ||| DT
Zung  ||| S:1016 E:1021 ||| JJ
depression  ||| S:1021 E:1032 ||| NN
( ||| S:1032 E:1033 ||| -LRB-
ZSDS ||| S:1033 E:1037 ||| NNP
)  ||| S:1037 E:1039 ||| -RRB-
and  ||| S:1039 E:1043 ||| CC
anxiety  ||| S:1043 E:1051 ||| NN
scales  ||| S:1051 E:1058 ||| NNS
( ||| S:1058 E:1059 ||| -LRB-
ZSAS ||| S:1059 E:1063 ||| NNP
) ||| S:1063 E:1064 ||| -RRB-
.  ||| S:1064 E:1066 ||| .
30 ||| S:1066 E:1068 ||| CD
/ ||| S:1068 E:1069 ||| CD
35  ||| S:1069 E:1072 ||| CD
patients  ||| S:1072 E:1081 ||| NNS
( ||| S:1081 E:1082 ||| -LRB-
85.7 ||| S:1082 E:1086 ||| CD
% ||| S:1086 E:1087 ||| NN
)  ||| S:1087 E:1089 ||| -RRB-
felt  ||| S:1089 E:1094 ||| VBD
unduly  ||| S:1094 E:1101 ||| RB
tired  ||| S:1101 E:1107 ||| JJ
and  ||| S:1107 E:1111 ||| CC
the  ||| S:1111 E:1115 ||| DT
same  ||| S:1115 E:1120 ||| JJ
percentage  ||| S:1120 E:1131 ||| NN
of  ||| S:1131 E:1134 ||| IN
patients  ||| S:1134 E:1143 ||| NNS
suffered  ||| S:1143 E:1152 ||| VBD
with  ||| S:1152 E:1157 ||| IN
pain  ||| S:1157 E:1162 ||| NN
in  ||| S:1162 E:1165 ||| IN
more  ||| S:1165 E:1170 ||| JJR
than  ||| S:1170 E:1175 ||| IN
one  ||| S:1175 E:1179 ||| CD
area  ||| S:1179 E:1184 ||| NN
of  ||| S:1184 E:1187 ||| IN
the  ||| S:1187 E:1191 ||| DT
body.  ||| S:1191 E:1197 ||| CD
7  ||| S:1197 E:1199 ||| CD
patients  ||| S:1199 E:1208 ||| NNS
satisfied  ||| S:1208 E:1218 ||| VBN
ACR  ||| S:1218 E:1222 ||| NNP
criteria  ||| S:1222 E:1231 ||| NNS
for  ||| S:1231 E:1235 ||| IN
FM ||| S:1235 E:1237 ||| NNP
,  ||| S:1237 E:1239 ||| ,
representing  ||| S:1239 E:1252 ||| VBG
20 ||| S:1252 E:1254 ||| CD
%  ||| S:1254 E:1256 ||| NN
of  ||| S:1256 E:1259 ||| IN
the  ||| S:1259 E:1263 ||| DT
whole  ||| S:1263 E:1269 ||| JJ
cohort  ||| S:1269 E:1276 ||| NN
and  ||| S:1276 E:1280 ||| CC
23 ||| S:1280 E:1282 ||| CD
%  ||| S:1282 E:1284 ||| NN
of  ||| S:1284 E:1287 ||| IN
SS  ||| S:1287 E:1290 ||| NNP
patients  ||| S:1290 E:1299 ||| NNS
with  ||| S:1299 E:1304 ||| IN
fatigue ||| S:1304 E:1311 ||| NN
.  ||| S:1311 E:1313 ||| .
No  ||| S:1313 E:1316 ||| DT
differences  ||| S:1316 E:1328 ||| NNS
were  ||| S:1328 E:1333 ||| VBD
found  ||| S:1333 E:1339 ||| VBN
in  ||| S:1339 E:1342 ||| IN
disease  ||| S:1342 E:1350 ||| NN
duration ||| S:1350 E:1358 ||| NN
,  ||| S:1358 E:1360 ||| ,
SSDDI ||| S:1360 E:1365 ||| NNP
,  ||| S:1365 E:1367 ||| ,
SSDAI ||| S:1367 E:1372 ||| NNP
,  ||| S:1372 E:1374 ||| ,
ZSDS  ||| S:1374 E:1379 ||| NNP
and  ||| S:1379 E:1383 ||| CC
ZSAS  ||| S:1383 E:1388 ||| NNP
among  ||| S:1388 E:1394 ||| IN
SS  ||| S:1394 E:1397 ||| NNP
patient  ||| S:1397 E:1405 ||| NN
with  ||| S:1405 E:1410 ||| IN
or  ||| S:1410 E:1413 ||| CC
without  ||| S:1413 E:1421 ||| IN
FM ||| S:1421 E:1423 ||| NNP
.  ||| S:1423 E:1425 ||| .
In  ||| S:1425 E:1428 ||| IN
the  ||| S:1428 E:1432 ||| DT
whole  ||| S:1432 E:1438 ||| JJ
group ||| S:1438 E:1443 ||| NN
,  ||| S:1443 E:1445 ||| ,
fatigue  ||| S:1445 E:1453 ||| VBG
VAS  ||| S:1453 E:1457 ||| NNP
correlated  ||| S:1457 E:1468 ||| NN
with  ||| S:1468 E:1473 ||| IN
HAQ ||| S:1473 E:1476 ||| NNP
,  ||| S:1476 E:1478 ||| ,
ZSAS ||| S:1478 E:1482 ||| NNP
,  ||| S:1482 E:1484 ||| ,
ZSDS  ||| S:1484 E:1489 ||| NNP
and  ||| S:1489 E:1493 ||| CC
pain  ||| S:1493 E:1498 ||| NN
VAS  ||| S:1498 E:1502 ||| NNP
but  ||| S:1502 E:1506 ||| CC
not  ||| S:1506 E:1510 ||| RB
with  ||| S:1510 E:1515 ||| IN
age ||| S:1515 E:1518 ||| NN
,  ||| S:1518 E:1520 ||| ,
disease  ||| S:1520 E:1528 ||| NN
duration ||| S:1528 E:1536 ||| NN
,  ||| S:1536 E:1538 ||| ,
presence  ||| S:1538 E:1547 ||| NN
and  ||| S:1547 E:1551 ||| CC
severity  ||| S:1551 E:1560 ||| NN
of  ||| S:1560 E:1563 ||| IN
arthritis ||| S:1563 E:1572 ||| NN
,  ||| S:1572 E:1574 ||| ,
SSDDI ||| S:1574 E:1579 ||| NNP
,  ||| S:1579 E:1581 ||| ,
SSDAI ||| S:1581 E:1586 ||| NNP
,  ||| S:1586 E:1588 ||| ,
or  ||| S:1588 E:1591 ||| CC
cytokines ||| S:1591 E:1600 ||| NN
.  ||| S:1600 E:1602 ||| .
In  ||| S:1602 E:1605 ||| IN
conclusion ||| S:1605 E:1615 ||| NN
,  ||| S:1615 E:1617 ||| ,
an  ||| S:1617 E:1620 ||| DT
overlapping  ||| S:1620 E:1632 ||| JJ
FM  ||| S:1632 E:1635 ||| NN
can  ||| S:1635 E:1639 ||| MD
contribute  ||| S:1639 E:1650 ||| VB
to ||| S:1650 E:1652 ||| TO
,  ||| S:1652 E:1654 ||| ,
but  ||| S:1654 E:1658 ||| CC
does  ||| S:1658 E:1663 ||| VBZ
not  ||| S:1663 E:1667 ||| RB
entirely  ||| S:1667 E:1676 ||| RB
account  ||| S:1676 E:1684 ||| VBP
for  ||| S:1684 E:1688 ||| IN
fatigue  ||| S:1688 E:1696 ||| NN
in  ||| S:1696 E:1699 ||| IN
Italian  ||| S:1699 E:1707 ||| JJ
patients  ||| S:1707 E:1716 ||| NNS
with  ||| S:1716 E:1721 ||| IN
primary  ||| S:1721 E:1729 ||| JJ
SS ||| S:1729 E:1731 ||| NNP
.  ||| S:1731 E:1733 ||| .
